Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Objective: Tacrolimus is an immunosuppressant commonly administered after solid organ transplantation. It is characterized by a narrow therapeutic window and high variability in exposure, demanding personalized dosing. In recent years, population pharmacokinetic models have been suggested to guide model-informed precision dosing of tacrolimus. We aimed to provide a comprehensive overview of population pharmacokinetic models and model-informed precision dosing software modules of tacrolimus in all solid organ transplant settings, including a simulation-based investigation of the impact of covariates on exposure and target attainment.

Methods: We performed a systematic literature search to identify population pharmacokinetic models of tacrolimus in solid organ transplant recipients. We integrated selected population pharmacokinetic models into an interactive software tool that allows dosing simulations, Bayesian forecasting, and investigation of the impact of covariates on exposure and target attainment. We conducted a web survey amongst model-informed precision dosing software tool providers and benchmarked publicly available tools in terms of models, target populations, and clinical integration.

Results: We identified 80 population pharmacokinetic models, including 44 one-compartment and 36 two-compartment models. The most frequently retained covariates on clearance and distribution parameters were cytochrome P450 3A5 polymorphisms and body weight, respectively. Our simulation tool, hosted at https://lpmx.shinyapps.io/tacrolimus/ , allows thorough investigation of the impact of covariates on exposure and target attainment. We identified 15 model-informed precision dosing software tool providers, of which ten offer a tacrolimus solution and nine completed the survey.

Conclusions: Our work provides a comprehensive overview of the landscape of available tacrolimus population pharmacokinetic models and model-informed precision dosing software modules. Our simulation tool allows an interactive thorough exploration of covariates on exposure and target attainment.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-024-01414-yDOI Listing

Publication Analysis

Top Keywords

population pharmacokinetic
28
pharmacokinetic models
28
model-informed precision
24
precision dosing
24
dosing software
16
covariates exposure
16
exposure target
16
solid organ
12
investigation impact
12
impact covariates
12

Similar Publications

The diamide insecticide cyantraniliprole (CYA) and the triazole fungicide difenoconazole (DIF) are frequently co-detected in bee-related matrices. However, the interactive effects of these compounds on honey bee (Apis mellifera L.) physiology remain insufficiently elucidated.

View Article and Find Full Text PDF

Background: Standard Unified BioAccessibility Research Group of Europe (BARGE) Method (UBM) protocols for metal bioaccessibility assessment face challenges due to post-acidification precipitation, causing significant methodological inconsistencies across studies. This research systematically examined precipitate formation by characterizing protein-metal interactions and identifying specific proteins involved, leading to development of an enhanced UBM method for more reliable metal bioaccessibility measurements in consumer products. We focused on precipitation caused by acid injection during sample storage for subsequent instrumental analysis.

View Article and Find Full Text PDF

Optimizing Linezolid Dosing for Nosocomial Urinary Tract Infections in Critically Ill Patients with Renal Impairment.

Int J Antimicrob Agents

September 2025

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China; National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China. Electronic address:

Background: This study characterized the urinary pharmacokinetics and pharmacodynamics (PK/PD) of linezolid (LNZ) in critically ill patients with renal impairment and nosocomial multidrug-resistant Gram-positive urinary tract infections (UTIs). The aim was to address therapeutic challenges arising from limited treatment options and uncertain urinary excretion, to establish optimized dosing strategies.

Methods: A prospective observational study was conducted in ICU patients with renal impairment.

View Article and Find Full Text PDF

Oral drug treatments of erectile dysfunction: a AFU/SFMS systematic review.

Fr J Urol

September 2025

Department of urology, Maison de Santé Protestante de Bordeaux-Bagatelle, Talence, France; Department of urology, HIA Robert-Picqué, Villenave d'Ornon, France.

Objectives: To evaluate the efficacy and safety of oral phosphodiesterase-5 inhibitors (PDE5Is) in the treatment of erectile dysfunction (ED). Additionally, to compare various PDE5Is and assess their suitability for different patient populations.

Evidence Acquisition: A systematic review of literature published from January 1999 to January 2023 was conducted following the PICOS criteria.

View Article and Find Full Text PDF

Background: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.

Methods: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries.

View Article and Find Full Text PDF